Supported by an unrestricted research grant of €3.9MM from Sanofi, we are now able to launch the next step of DiaUnion.
The DiaUnion autoantibody screening 2.0 program is established to identifying people pre-symptomatic for type 1 diabetes and the related autoimmune diseases, celiac disease and autoimmune thyroid disease. The DiaUnion autoantibody screening 2.0 program is expected to find a total 7,030 aab positive individuals over the course of 3 years in Sweden and Denmark. Of these, 2,196 will be T1D aab positive, and 1,244 will have two or more T1D aabs (stage 1+2) within the 3 years of the program.
The ambition of DiaUnion is to develop a model for establishment of permanent type 1 diabetes (and related autoimmune diseases) screening programs. DiaUnion 2.0 launches July 1, 2024.
Press releases in Swedish and Danish here.
